Aurum Biosciences

Executive Summary

Aurum Biosciences is a UK-based clinical-stage biopharmaceutical company pioneering novel oxygen carriers for therapeutic and diagnostic applications. Its lead candidate targets acute ischemic stroke (AIS), a condition with high unmet need where timely restoration of oxygen supply is critical. The company's technology leverages proprietary oxygen-carrier molecules designed to enhance oxygen delivery to ischemic tissues, potentially improving outcomes beyond standard reperfusion therapies. Additionally, Aurum is developing inflammation imaging agents based on the same platform, which could enable early detection of inflammatory processes in conditions such as stroke, heart disease, and spinal cord injury. The company has raised funding from venture capital and government grants, and its pipeline extends to cardiac arrest, oncology, and traumatic brain injury. Aurum is currently advancing its lead asset through Phase 2 clinical development for AIS. If successful, the therapy could become a first-in-class adjunct to thrombolysis or thrombectomy, addressing a market spanning millions of stroke patients annually. The imaging diagnostic program also holds promise for non-invasive monitoring of inflammation. Key upcoming milestones include Phase 2 data readout, potential strategic partnerships for the imaging platform, and IND filings for follow-on indications. With a novel mechanism and broad applicability, Aurum represents an early-stage but high-potential play in the oxygen therapeutics space.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout in acute ischemic stroke55% success
• Q4 2026Strategic partnership for inflammation imaging diagnostic40% success
• Q1 2027IND submission for follow-on indication (e.g., cardiac arrest)50% success